Novo Nordisk Valuation: Assessing Recent Share Price Performance and Future Growth Potential.

Novo Nordisk's share price has rebounded with a 25.65% increase in the past month and a 17.94% year-to-date gain. Despite a 30.15% total shareholder return decline in the past year, the recent momentum has picked up. Analysts have a consensus price target of DKK465.3, with a fair value of DKK392.29, indicating the stock is undervalued in intrinsic terms. However, there are still risks, including potential pricing pressure on key GLP 1 drugs and legal or regulatory challenges that could impact growth.